The Board of Directors of the Company at their meeting held on 14.11.2022 have approved the Memorandum of Understanding ('MOU') for the proposed merger of MVK Lifesciences Private Limited ('MVK') into the Company subject to requisite approvals, permissions and consents, . With reference to the captioned subject, we hereby intimate you that after considering the recommendation and report of the Audit Committee and the Committee of Independent Directors, the Board of Directors of the Company in the meeting held on December 16, 2022 at the Registered office of the Company situated at 601, Hyde Park, CTS No. 680 Saki Vihar Rd, Saki Naka, Mumbai- 400072, Maharashtra have considered and approved the Scheme of merger of MVK Lifesciences Private Limited with the Company pursuant to Sections 230 to 232 of the Companies Act, 2013 Remarks: Price: Price mentioned above is price per share of MVK Lifesciences Private Limited as determined by the registered Valuer in his valuation report Payment date: Payment date is taken as the date of board meeting wherein scheme of merger has been approved. Actual payment is in the form of issue of shares of the Transferee company post approval of scheme of merger by Hon. NCLT. (As Per BSE Announcement Dated on 16/12/2022) This is to inform you that after considering the recommendation and report of the Audit Committee and the Committee of Independent Directors, the Board of Directors of Remedium Lifecare Limited ('the Company') at the meeting held on December 16, 2022 have considered and approved Scheme of merger of MVK Lifesciences Private Limited with the Company pursuant to Sections 230 to 232 of the Companies Act, 2013 ('Scheme'). The Scheme is subject to receipt of requisite statutory and regulatory approvals including that of shareholders and creditors of each of the Companies, as may be required, BSE Limited and Hon'ble National Company Law Tribunal, Mumbai Bench. The Scheme shall be filed with the Stock Exchanges in terms of the provisions of Regulation 37 (1) of SEBI (LODR)_Regulations, 2015 in due course. The details pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 in respect of the Scheme is enclosed. (As Per BSE Announcement Dated on 17/12/2022) Outcome of Board Meeting held on 30.05.2023 The Board of Directors of the Company in its meeting held on 30th May, 2023, had taken up the discussion regarding status of approval for the Scheme of amalgamation between MVK Lifesciences Private Limited ('Transferor Company) and Remedium Lifecare Limited ('Transferee Company') and their respective shareholders ('the Scheme') filed with BSE India on 7th January, 2023. After due deliberation, the Board is of the view that it would be prudent to not proceed with the Scheme and keeping in mind the strategic interest, to explore other options to achieve the desired synergies. Accordingly, it has decided to withdraw the Scheme with immediate effect. (As Per BSE Announcement dated on 30.05.2023)